Discovery Research-Medicinal Chemistry, Suven Life Sciences Ltd., Banjara Hills, Hyderabad, India.
J Enzyme Inhib Med Chem. 2012 Jun;27(3):443-50. doi: 10.3109/14756366.2011.595713. Epub 2011 Jul 21.
5-Hydroxytryptamine 6 receptors (5-HT(6)R) are being perceived as the possible target for treatment of cognitive disorders as well as obesity. The present article deals with the design, synthesis, in vitro binding and structure-activity relationship of a novel series of tetracyclic tryptamines with the rigidized N-arylsulphonyl, N-arylcarbonyl and N-benzyl substituents as 5-HT(6) receptor ligands. The chiral sulphonyl derivatives 15a and 17a showed high affinity at 5-HT(6)R with the K(i) of 23.4 and 20.5 nM, respectively. The lead compound from the series 15a has acceptable ADME properties, adequate brain penetration and is active in animal models of cognition like Novel Object Recognition Task (NORT) and water maze.
5-羟色胺 6 受体(5-HT6R)被认为是治疗认知障碍和肥胖的可能靶点。本文设计、合成了一系列新型四环色胺,这些化合物具有刚性的 N-芳磺酰基、N-芳羰基和 N-苄基取代基,作为 5-HT6 受体配体。手性磺酰基衍生物 15a 和 17a 对 5-HT6R 具有高亲和力,Ki 值分别为 23.4 和 20.5 nM。该系列的先导化合物 15a 具有可接受的 ADME 特性、足够的脑穿透性,并在认知动物模型(如新物体识别任务和水迷宫)中具有活性。